Megha Basak
Has grant
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
2025 Prostate Cancer Program Pilot Research Award
Open Date: 2025-01-01
Close Date: 2026-01-01
Grant: Close
MHRD GATE Fellowship
Open Date: 2017-01-01
Close Date: 2022-01-01
Grant: Close
PG Indira Gandhi Scholarship
Open Date: 2014-01-01
Close Date: 2016-01-01
Grant: Close
Scheme of Scholarship for College and University students(WBCHSE)
Open Date: 2011-01-01
Close Date: 2016-01-01
Grant: Close
Travel grant award 2026
Open Date:
Close Date:
Articles (40)
Purpose: CD46 is highly expressed across multiple cancer types, including prostate cancer and multiple myeloma. We have developed CD46-targeting antibody–drug conjugate (ADC) and actinium-225 (225Ac)–based α particle therapy agents that demonstrated a tumor-selective therapeutic effect. We hypothesized that a treatment strategy targeting CD46 using simultaneous ADC and radioimmunotherapy methods would have synergistic therapeutic efficacy with acceptable toxicity. Experimental Design: Two CD46-targeted combination treatment strategies were evaluated: (i) co-administration of the ADC (YS5-MMAE) and 225Ac-labeled antibody ([225Ac]Macropa-PEG4-YS5) and (ii) a dual-payload radioconjugate ([225Ac]Macropa-PEG4-YS5-MMAE; R-ADC). The in vitro synergy was studied using cell viability, DNA damage, and apoptosis assays. In vivo studies were performed for biodistribution, toxicity, and therapeutic evaluation in subcutaneous, disseminated, and patient-derived xenograft models of prostate cancer and multiple myeloma. Results: Combination therapy induced synergistic G2–M arrest, increased γ-H2AX foci, and enhanced cell death compared with monotherapies. R-ADC and co-administration strategies resulted in improved tumor control and survival benefit. Conclusions: By integrating orthogonal microtubule inhibition and high–linear energy transfer α irradiation on a single CD46 scaffold, potent, well-tolerated tumor control was achieved across diverse models. The dual-payload construct’s compatibility with CD46 immuno-PET for real-time dosimetry further supports progression to early-phase clinical trials in prostate cancer and multiple myeloma.
Year:
2026
Supplementary Table S2: The %IA/g values for biodistribution study of [89Zr]DFO-YS5 in PC3-Luc disseminated tumors, conducted 4 days post-injection (p.i.), utilized mice with PC3-Luc tumors at 5 weeks post-cell inoculations. The large intestine tissue from Mouse 1 was not recorded due to a technical error in the instrument.
Year:
2025
Supplementary Table S8: The %IA/g values for biodistribution of [89Zr]DFO-YS5 in the mice from early treatment (week 1 post inoculations) treated with 4.2 and 9.2 kBq of [225Ac]Macropa-PEG4-YS5.
Year:
2025
Purpose: Metastatic castration-resistant prostate cancer has limited treatment options and a poor prognosis. Recently, prostate-specific membrane antigen (PSMA)-targeted alpha-particle therapy agents using actinium-225 ( 225 Ac) have shown promising results in prostate cancer treatment, but a significant fraction of patients with advanced mCRPC demonstrate loss of PSMA expression. We have previously reported that PSMA-null and PSMA-positive tumors can be detected and treated effectively with CD46-targeted radiopharmaceuticals. This study evaluates the CD46-targeting PET imaging agent [ 89 Zr]DFO-YS5, and the radioimmunotherapy agent [ 225 Ac]Macropa-PEG 4 -YS5, in disseminated prostate cancer tumors. Experimental Design: Microtumor lesions, primarily observed in the liver, kidneys, and lungs, were successfully detected with [ 89 Zr]DFO-YS5 PET imaging. We used disseminated 22Rv1 tumors for biodistribution studies, dosimetry assessments, and therapeutic efficacy evaluations of [ 225 Ac]Macropa-PEG 4 -YS5. Results: Quantitative digital alpha-particle autoradiography revealed high radiation dose deposition from [ 225 Ac]Macropa-PEG 4 -YS5 in microtumors compared with surrounding liver tissues, although in larger lesions (>1 mm diameter), the dose distribution was heterogeneous. Early treatment of smaller disseminated tumors with a uniform radiation dose was more effective in ablating tumors and promoting survival. In late-stage lesions of large size, heterogeneous dose deposition limited therapeutic efficacy, requiring higher administered activity to achieve a complete response. Conclusions: Our findings highlight that [ 225 Ac]Macropa-PEG 4 -YS5 holds the potential for clinical translation for metastatic prostate cancer and reinforces the value of microdosimetry in understanding the efficacy of and resistance to targeted alpha therapy. See related commentary by Patel et al., p. 2847
Year:
2025
Supplementary Table S15. Organ biodistribution analysis data in %ID/g tissue for 89Zr labeled nanocarriers at 96 h in metastatic mice model with 22rv1 cell inoculated in kidney capsule tumors. (n = 4)
Year:
2025
Supplementary Figure S7. Coronal μPET/CT fusion and MIP images obtained at 24 h, 48 h, 72 h, and 96 h following administration of 150-170 μCi of 89Zr labeled nanocarriers in nude mice bearing LTL-610 patient derived xenograft (PDX) of tumors over left flanks.
Year:
2025
Supplementary Figure S6. Coronal μPET/CT fusion and MIP images obtained at 24 h, 48 h, 72 h, and 96 h following administration of 150-170 μCi of 89Zr labeled nanocarriers in nude mice bearing LTL-545 patient derived xenograft (PDX) of tumors over left flanks.
Year:
2025
Supplementary Figure S3. Ex vivo tumor biodistribution, (a) %ID per gram and (b) %ID per organ of nude mice bearing different tumor models including prostate cancer (22rv1, PC3, DU145), colorectal cancer (CT26), and pancreatic cancer (BxPC3) at 24h and 72 h post-injection of [89Zr]PEG-DFB1-TLZ3. The respective (c) tumor uptakes, (d) tumor to muscle ratio, and (e) tumor to blood ratio of the same mice. (n = 4, mean ± SD) (f) Autoradiographic images of tumor sections from mouse model bearing different preclinical cancer xenograft at 72h post-injection of [89Zr]PEG-DFB1-TLZ3.
Year:
2025
Supplementary Figure S19. Coronal μPET/CT fusion and MIP images obtained at 24 h, 48 h, 72 h, and 96 h following administration of 150-170 μCi of [89Zr]PEG-DFB1-TLZ3 in nude mice inoculated with 22rv1 cells in the left kidney capsule (red arrow). Yellow arrows indicate metastatic tumor.
Year:
2025
Supplementary Figure S1. (a) Zeta potential of the StarPEG conjugates PEG-DFB4 and PEG-DFB1-TLZ3 with an average surface charge of -4.04±0.21 mV and -1.41±0.22 mV, respectively (n = 3). (b) TEM images of PEG-DFB4 and PEG-DFB1-TLZ3 showing the formation of nanoparticles in the range of 10 to 15 nm. TEM samples were prepared by dropcasting the water solution (0.25 mg/mL) of respective StarPEG on carbon coated copper grid of 200 mesh.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Year:
2021
Collaborators (13)
Nancy Y. Greenland
-
Henry VanBrocklin
Professor/ Director of Radiopharmaceutical Research
University of California, San Francisco
Jiang He
Professor
University of Virginia
David M. Wilson
University of California
Renuka Sriram
University of California
Anil Parsram Bidkar
Assistant Professional Researcher
University of California, San Francisco
Jonathan Chou
Assistant Professor
University of California, San Francisco
Changhua Mu
Assistant Professional Researcher
University of California, San Francisco
Robert R. Flavell
University of California
Y. Seo
University of California, San Francisco
Rahul Aggarwal
University of California
Scott C. Kogan
University of California, San Francisco
kondapa Naidu Bobba
Assistant professor
University of Tennessee
Make your next move.
Prepare your application
Review drafts before you send them.